News | January 17, 2025
AbbVie partners with Simcere Zaiming to develop Novel Trispecific Antibody Candidate in Multiple Myeloma
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
Clinical studies are expected to start in Q2 2023.
This clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal anastomosis
Subscribe To Our Newsletter & Stay Updated
